Skip to main content

Larimar Therapeutics, Inc.

LRMR
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001374690

In the last 90 days, Larimar Therapeutics, Inc. insiders filed 1 open-market purchase and 0 sales; 163 institutions reported holding it in 13F filings for Q2 2026, worth $291.4M in total; no superinvestor holds it.

Q4 2023 vs. Q3 2023

How the institutions holding Larimar Therapeutics, Inc. changed between Q3 2023 and Q4 2023.

All holders in Q4 2023All holders in Q3 2023

13F holders of LRMR: Q3 2023 compared with Q4 2023
MeasureQ3 2023Of which not filed for Q4 2023Q4 2023Change
Holders65169+5
Shares38.7M3.41M39.5M+4.13M (+11.7%)
Value$153.0M$13.5M$179.6M+$40.0M (+28.7%)

1 institution that held it in Q3 2023 haven't filed for Q4 2023 yet. Not filing isn't selling, so the changes leave them out.

New holders (8)

Institutions that held Larimar Therapeutics, Inc. at the end of Q4 2023 but not at the end of Q3 2023.

Institutions new to LRMR in Q4 2023
InstitutionSharesValue% of portfolio
Blue Owl Capital Holdings LP3,414,468$15.5M3.71%
StemPoint Capital LP783,172$3.56M0.96%
Deutsche Bank AG272,373$1.24M0.00%
PEAK6 Investments LLC30,000$136.5K0.01%
Invesco Ltd.12,258$55.8K0.00%
Susquehanna International Group, LLP10,375$47.2K0.00%
BFSG, LLC2,000$9.10K0.00%
Tennessee Valley Asset Management Partners8$360.00%

Sold out (3)

Institutions that held Larimar Therapeutics, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.

Institutions that sold out of LRMR in Q4 2023
InstitutionShares, Q3 2023Value, Q3 2023
Connor, Clark & Lunn Investment Management Ltd.21,835$86.2K
Advisor Group Holdings, Inc.1,000$3.95K
CWM, LLC86$0

Not filed for Q4 2023 yet (1)

Institutions that held Larimar Therapeutics, Inc. at the end of Q3 2023 and haven't filed a 13F for Q4 2023. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding LRMR in Q3 2023 that haven't filed for Q4 2023
InstitutionShares, Q3 2023Value, Q3 2023
CHI Advisors LLC3,414,468$13.5M